In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii
Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing r...
Gespeichert in:
Veröffentlicht in: | Antimicrobial agents and chemotherapy 2021-08, Vol.65 (9), p.e0264620-e0264620 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e0264620 |
---|---|
container_issue | 9 |
container_start_page | e0264620 |
container_title | Antimicrobial agents and chemotherapy |
container_volume | 65 |
creator | Abdul-Mutakabbir, Jacinda C Nguyen, Logan Maassen, Philip T Stamper, Kyle C Kebriaei, Razieh Kaye, Keith S Castanheira, Mariana Rybak, Michael J |
description | Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates. |
doi_str_mv | 10.1128/AAC.02646-20 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8370208</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541319109</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-c154043a6700ca75eff9f881c13787e6b2ae434417adaadb98b80616b4fd336f3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoMo9lrduZZZWnDqycdkMhthuPhRqAiibsOZTHJNmUlqkin03xu9tejCVU7Ic55DzkvIcwrnlDL1ehz358CkkC2DB2RHYVCt7Ab5kOwApGyFAnFCnuR8BfXeDfCYnHBBWVfLHZkuQvPNlxSbMRQ_oSk2eVya0RR_48ttE12zt87PNkUTlwYP6EMuzcdtKX5O26H9bLPPBUOpPT7YEo-SZsJtxRC8f0oeOVyyfXZ3npKv795-2X9oLz-9v9iPly0KqkpraCdAcJQ9gMG-s84NTilqKO9Vb-XE0AouBO1xRpynQU0KJJWTcDPn0vFT8ubovd6m1c7GhpJw0dfJr5hudUSv_30J_rs-xButeA8MVBW8vBOk-GOzuejVZ2OXBYONW9asE5TToW64oq-OqEkx52Td_RgK-lcsusaif8eiGVT87IhjXpm-ilsKdRP_Y1_8_Y178Z_M-E-175a4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541319109</pqid></control><display><type>article</type><title>In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii</title><source>MEDLINE</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Abdul-Mutakabbir, Jacinda C ; Nguyen, Logan ; Maassen, Philip T ; Stamper, Kyle C ; Kebriaei, Razieh ; Kaye, Keith S ; Castanheira, Mariana ; Rybak, Michael J</creator><creatorcontrib>Abdul-Mutakabbir, Jacinda C ; Nguyen, Logan ; Maassen, Philip T ; Stamper, Kyle C ; Kebriaei, Razieh ; Kaye, Keith S ; Castanheira, Mariana ; Rybak, Michael J</creatorcontrib><description>Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.02646-20</identifier><identifier>PMID: 34125590</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Acinetobacter baumannii ; Anti-Bacterial Agents - pharmacology ; Cefiderocol ; Cephalosporins - pharmacology ; Drug Resistance, Multiple, Bacterial ; Mechanisms of Resistance ; Microbial Sensitivity Tests</subject><ispartof>Antimicrobial agents and chemotherapy, 2021-08, Vol.65 (9), p.e0264620-e0264620</ispartof><rights>Copyright © 2021 American Society for Microbiology.</rights><rights>Copyright © 2021 American Society for Microbiology. 2021 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-c154043a6700ca75eff9f881c13787e6b2ae434417adaadb98b80616b4fd336f3</citedby><cites>FETCH-LOGICAL-a418t-c154043a6700ca75eff9f881c13787e6b2ae434417adaadb98b80616b4fd336f3</cites><orcidid>0000-0003-2220-0081 ; 0000-0003-0126-1782</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370208/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370208/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34125590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdul-Mutakabbir, Jacinda C</creatorcontrib><creatorcontrib>Nguyen, Logan</creatorcontrib><creatorcontrib>Maassen, Philip T</creatorcontrib><creatorcontrib>Stamper, Kyle C</creatorcontrib><creatorcontrib>Kebriaei, Razieh</creatorcontrib><creatorcontrib>Kaye, Keith S</creatorcontrib><creatorcontrib>Castanheira, Mariana</creatorcontrib><creatorcontrib>Rybak, Michael J</creatorcontrib><title>In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.</description><subject>Acinetobacter baumannii</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Cefiderocol</subject><subject>Cephalosporins - pharmacology</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Mechanisms of Resistance</subject><subject>Microbial Sensitivity Tests</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1rFTEUhoMo9lrduZZZWnDqycdkMhthuPhRqAiibsOZTHJNmUlqkin03xu9tejCVU7Ic55DzkvIcwrnlDL1ehz358CkkC2DB2RHYVCt7Ab5kOwApGyFAnFCnuR8BfXeDfCYnHBBWVfLHZkuQvPNlxSbMRQ_oSk2eVya0RR_48ttE12zt87PNkUTlwYP6EMuzcdtKX5O26H9bLPPBUOpPT7YEo-SZsJtxRC8f0oeOVyyfXZ3npKv795-2X9oLz-9v9iPly0KqkpraCdAcJQ9gMG-s84NTilqKO9Vb-XE0AouBO1xRpynQU0KJJWTcDPn0vFT8ubovd6m1c7GhpJw0dfJr5hudUSv_30J_rs-xButeA8MVBW8vBOk-GOzuejVZ2OXBYONW9asE5TToW64oq-OqEkx52Td_RgK-lcsusaif8eiGVT87IhjXpm-ilsKdRP_Y1_8_Y178Z_M-E-175a4</recordid><startdate>20210817</startdate><enddate>20210817</enddate><creator>Abdul-Mutakabbir, Jacinda C</creator><creator>Nguyen, Logan</creator><creator>Maassen, Philip T</creator><creator>Stamper, Kyle C</creator><creator>Kebriaei, Razieh</creator><creator>Kaye, Keith S</creator><creator>Castanheira, Mariana</creator><creator>Rybak, Michael J</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2220-0081</orcidid><orcidid>https://orcid.org/0000-0003-0126-1782</orcidid></search><sort><creationdate>20210817</creationdate><title>In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii</title><author>Abdul-Mutakabbir, Jacinda C ; Nguyen, Logan ; Maassen, Philip T ; Stamper, Kyle C ; Kebriaei, Razieh ; Kaye, Keith S ; Castanheira, Mariana ; Rybak, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-c154043a6700ca75eff9f881c13787e6b2ae434417adaadb98b80616b4fd336f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acinetobacter baumannii</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Cefiderocol</topic><topic>Cephalosporins - pharmacology</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Mechanisms of Resistance</topic><topic>Microbial Sensitivity Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdul-Mutakabbir, Jacinda C</creatorcontrib><creatorcontrib>Nguyen, Logan</creatorcontrib><creatorcontrib>Maassen, Philip T</creatorcontrib><creatorcontrib>Stamper, Kyle C</creatorcontrib><creatorcontrib>Kebriaei, Razieh</creatorcontrib><creatorcontrib>Kaye, Keith S</creatorcontrib><creatorcontrib>Castanheira, Mariana</creatorcontrib><creatorcontrib>Rybak, Michael J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdul-Mutakabbir, Jacinda C</au><au>Nguyen, Logan</au><au>Maassen, Philip T</au><au>Stamper, Kyle C</au><au>Kebriaei, Razieh</au><au>Kaye, Keith S</au><au>Castanheira, Mariana</au><au>Rybak, Michael J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2021-08-17</date><risdate>2021</risdate><volume>65</volume><issue>9</issue><spage>e0264620</spage><epage>e0264620</epage><pages>e0264620-e0264620</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>34125590</pmid><doi>10.1128/AAC.02646-20</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2220-0081</orcidid><orcidid>https://orcid.org/0000-0003-0126-1782</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0066-4804 |
ispartof | Antimicrobial agents and chemotherapy, 2021-08, Vol.65 (9), p.e0264620-e0264620 |
issn | 0066-4804 1098-6596 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8370208 |
source | MEDLINE; PubMed Central; EZB Electronic Journals Library |
subjects | Acinetobacter baumannii Anti-Bacterial Agents - pharmacology Cefiderocol Cephalosporins - pharmacology Drug Resistance, Multiple, Bacterial Mechanisms of Resistance Microbial Sensitivity Tests |
title | In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A33%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Antibacterial%20Activity%20of%20Cefiderocol%20against%20Multidrug-Resistant%20Acinetobacter%20baumannii&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Abdul-Mutakabbir,%20Jacinda%20C&rft.date=2021-08-17&rft.volume=65&rft.issue=9&rft.spage=e0264620&rft.epage=e0264620&rft.pages=e0264620-e0264620&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.02646-20&rft_dat=%3Cproquest_pubme%3E2541319109%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541319109&rft_id=info:pmid/34125590&rfr_iscdi=true |